Author Archives: Guest Blogger

Mind the (Generation) Gap: The Hunt for Talent in Asia

As more global life sciences firms see their Asian businesses skyrocket, the search for strong, internationally savvy talent in Asia-Pacific has never been more competitive, writes Susan Macdonald of RSA. The need to build manufacturing and commercial infrastructure in Asia-Pacific with the associated regulatory, quality and compliance processes to satisfy Western authorities is reaching new […]
Posted in Emerging Markets, Global, Guest Blog, leadership | Tagged , , , , | Leave a comment

Sponsor–CMO Relationships: Critical Issues

Eric Langer assesses the results of a recent survey of what biopharm companies want from CMOs. Contract manufacturing organizations (CMOs) should have the technical expertise to be considered by clients for partnerships. It’s no longer enough for them to lay claim to technology, regulatory compliance, and IP protection expertise, as these increasingly become non-negotiable issues, according […]
Posted in Biotech | Tagged , , | Leave a comment

The Future of Oncology is Now

Applied Clinical Trials’ Lisa Henderson speaks to Novella Clinical CEO Richard Staub. Last August, Quintiles announced its intention to purchase Novella Clinical, specifically for its focus on small and mid-sized oncology biopharma clients, as well as medical device and diagnostics companies. We checked in with Novella President Richard Staub to discuss post-acquisition life, outsourcing, and […]
Posted in R&D | Tagged , , , | Leave a comment

Medical Marijuana Trials: Pre-empted by Politics

There has been a lot of debate on the therapeutic use of marijuana. There are currently 24 states that have legalized marijuana for medical use. Most recently, two states, Washington and Colorado, have legalised the drug for recreational use. While there is literature that suggests benefits of marijuana for medicinal use, particularly in animal models, […]
Posted in Guest Blog, healthcare, People, R&D | Tagged , , , , | Leave a comment

M&As: Past, Present, and Future

Pharmaceutical Technology’s Faiz Kermani looks at the long history of pharma mergers and finds no sign of the trend slowing down. It was suggested that in one week of April the total value of various rumored deals was of the order of US$100 billion, illustrating how cash-rich major pharmaceutical companies are. Many of the larger […]
Posted in Deals, Emerging Markets, Europe, Global, Guest Blog, R&D, Strategy | Tagged , , | Leave a comment
  • Categories

  • Meta